Efficacy and safety of anlotinib plus camrelizumab in treating retroperitoneal soft tissue sarcomas: a single-center retrospective cohort study

BACKGROUND: Conventional chemotherapy has limited therapeutic effects in retroperitoneal soft tissue sarcomas (RSTs), while anlotinib emerged as a novel multi-target tyrosine kinase inhibitor (TKI) for sarcomas. TKIs in combination with immunotherapy have demonstrated clinical activity in a variety...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Jianhui, Li, Chengpeng, Liu, Bonan, Liu, Qiao, Liu, Daoning, Wang, Zhen, Wang, Xiaopeng, Jia, Weiwei, Tian, Xiuyun, Hao, Chunyi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061478/
https://www.ncbi.nlm.nih.gov/pubmed/37007540
http://dx.doi.org/10.21037/atm-23-460

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10061478/
https://www.ncbi.nlm.nih.gov/pubmed/37007540
http://dx.doi.org/10.21037/atm-23-460

Ejemplares similares